Bio-Techne (TECH) analyst forecast and price target
Analyst forecast
Consensus of 17 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $73.00 from $62.00 | Aug 13, 2026 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $73.00 from $62.00 | Jul 9, 2026 |
| Benchmark | Downgraded | Buy → Hold | — | Jun 30, 2026 |
| TD Cowen | Downgraded | Buy → Hold | $73.00 from $65.00 | Jun 30, 2026 |
| Citigroup | Downgraded | Buy → Neutral | $73.00 from $70.00 | Jun 29, 2026 |
| William Blair | Downgraded | Outperform → Market Perform | — | Jun 26, 2026 |
| Stephens & Co. | Downgraded | Overweight → Equal-Weight | $73.00 from $68.00 | Jun 26, 2026 |
| Baird | Maintained | Neutral | $73.00 from $49.00 | Jun 26, 2026 |
| Piper Sandler | Initiated Coverage | Neutral | $65.00 | Jun 11, 2026 |
| RBC Capital | Maintained | Outperform | $62.00 | May 15, 2026 |
| Evercore ISI Group | Maintained | In-Line | $50.00 from $54.00 | May 7, 2026 |
| Wells Fargo | Maintained | Overweight | $62.00 from $76.00 | May 7, 2026 |
| Citigroup | Maintained | Buy | $70.00 from $80.00 | May 7, 2026 |
| Evercore ISI Group | Maintained | In-Line | $54.00 from $68.00 | Apr 6, 2026 |
| Wells Fargo | Maintained | Overweight | $76.00 from $70.00 | Feb 6, 2026 |
| Evercore ISI Group | Maintained | In-Line | $68.00 from $62.00 | Feb 5, 2026 |
| UBS | Maintained | Buy | $79.00 from $70.00 | Feb 5, 2026 |
| TD Cowen | Maintained | Buy | $80.00 from $70.00 | Feb 5, 2026 |
| Stifel | Maintained | Hold | $65.00 from $60.00 | Feb 5, 2026 |
| Citigroup | Maintained | Buy | $80.00 from $70.00 | Feb 5, 2026 |
Frequently asked questions
What is the price target for TECH stock?
The average 12-month analyst price target for Bio-Techne (TECH) is $71.86, with a high estimate of $73.00 and a low of $65.00, across 7 analysts.
Is TECH a buy, sell, or hold?
Analysts covering Bio-Techne currently average a Hold rating: 2 buy, 15 hold and 0 sell, from 17 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for TECH?
The average price target of $71.86 implies 0.65% downside from the last price of $72.33.
What is the latest analyst rating on TECH?
On Aug 13, 2026, Wells Fargo downgraded Bio-Techne to Equal-Weight with a price target of $73.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.